Virologica Sinica

, Volume 23, Issue 6, pp 486–495

Prevention and treatment of KSHV-associated diseases with antiviral drugs

Article

Abstract

Kaposi’s sarcoma-associated herpesvirus (KSHV) was first identified as the etiologic agent of Kaposi’s sarcoma (KS) in 1994. KSHV infection is necessary, but not sufficient for the development of Kaposi sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman disease (MCD). Advances in the prevention and treatment of KSHV-associated Diseases have been achieved, even though current treatment options are ineffective, or toxic to many affected persons. The identification of new targets for potential future therapies and the randomized trial to evaluate the efficacy of new antivirals are required.

Key words

Antiviral drugs Kaposi’s sarcoma-associated herpesvirus (KSHV) Kaposi’s sarcoma (KS) Primary effusion lymphoma Multicentric castleman disease 

CLC number

Q786 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Aaron L, Lidove O, Yousry C,et al. 2002. Human herpesvirus 8-positive Castleman disease in human immunodeficiency virus-infected patients: the impact of highly active antiretroviral therapy. Clin Infect Dis, 35: 880–882.PubMedCrossRefGoogle Scholar
  2. 2.
    Abele G, Cox S, Bergman L,et al. 1991. Antiviral activity against VZV and HSV type 1 and type 2 of the (+) and (−) enantiomers of (R,S)-9-[4-hydroxy-2-(hydroxymethyl) butyl] guanine, in comparison to other closely related acyclic nucleosides. Antiviral Chem Chemother, 2: 163–169.Google Scholar
  3. 3.
    Alagiozoglou L, Morris L, Bredell H,et al. 2003. Human herpesvirus-8 antibodies and DNA in HIV-1 infected patients in South Africa. Epidemiol Infect, 131: 1125–1129.PubMedCrossRefGoogle Scholar
  4. 4.
    Bahl S, Theis B, Nishri D,et al. 2008. Changing incidence of AIDS-related Kaposi sarcoma and non-Hodgkin lymphoma in Ontario, Canada. Cancer Causes Control, http://www.springerlink.com/content/y1423n681-4037804/fulltext.pdf
  5. 5.
    Bani-Sadr F, Fournier S, Molina J M. 2003. Relapse ofKaposi’s sarcoma inHIV-infected patients switching fromaprotease inhibitor toanon-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy regimen. AIDS, 17:1580–1581.PubMedCrossRefGoogle Scholar
  6. 6.
    Barillari G, Buonaguro L, Fiorelli V,et al. 1992. Effects of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression: implications for AIDS-Kaposi’s sarcoma pathogenesis. J Immunol, 149: 3727–3734.PubMedGoogle Scholar
  7. 7.
    Beral V. 1991. Epidemiology of Kaposi’s sarcoma. Cancer Surv, 10: 5–22.PubMedGoogle Scholar
  8. 8.
    Berezne A, Agbalika F, Oksenhendler E,et al. 2004. Failure of cidofovir in HIV-associated multicentric Castleman disease. Blood, 103: 4368–4369.PubMedCrossRefGoogle Scholar
  9. 9.
    Biggar R J, Whitby D, Marshall V,et al. 2000. Human herpesvirus 8 in Brazilian Amerindians: a hyperendemic population with a new subtype. J Infect Dis, 181: 1562–1568.PubMedCrossRefGoogle Scholar
  10. 10.
    Bottieau E, Colebunders R, Schroyens W,et al. 2000. Multicentric Castleman’s disease in 2 patients with HIV infection, unresponsive to antiviral therapy. Acta Clin Belg, 55: 97–101.PubMedGoogle Scholar
  11. 11.
    Bower M, Fox P, Fife K,et al. 1999. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi’s sarcoma. AIDS, 13: 2105–2111.PubMedCrossRefGoogle Scholar
  12. 12.
    Casper C, Nichols W G, Huang M L,et al. 2004. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood, 103: 1632–1634.PubMedCrossRefGoogle Scholar
  13. 13.
    Cattelan A, Calabro M, Gasperini P,et al. 2001. Acquired immunodeficiency syndrome-related Kaposi’s sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome. J Natl Cancer Inst Monogr, 28: 44–49.PubMedGoogle Scholar
  14. 14.
    Chang Y, Cesarman E, Pessin M S,et al. 1994. Identification of herpesvirus-like sequences in AIDS-associated Kaposi’s sarcoma. Science, 266: 1865–1869.PubMedCrossRefGoogle Scholar
  15. 15.
    Clifford G M, Polesel J, Rickenbach M,et al. 2005. Cancer Risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst, 97: 425–432PubMedCrossRefGoogle Scholar
  16. 16.
    Crum-Cianflone N F, Wallace M R, Looney D. 2006. Successful secondary prophylaxis for primary effusion lymphoma with human herpesvirus 8 therapy. AIDS, 20: 1567–1569.PubMedCrossRefGoogle Scholar
  17. 17.
    Dilnur P, Katano H, Wang Z H,et al. 2001. Classic type of Kaposi’s sarcoma and human herpesvirus 8 infection in Xinjiang, China. Pathol Int, 51: 845–852.PubMedCrossRefGoogle Scholar
  18. 18.
    Diz Dios P, Ocampo Hermida A, Miralles Alvarez C,et al. 1998. Regression of AIDS-related Kaposi’s sarcoma following ritonavir therapy. Oral Oncol, 34: 236–238.PubMedCrossRefGoogle Scholar
  19. 19.
    Dukers N H, Rezza G. 2003. Human herpesvirus 8 epidemiology: what we do and do not know. AIDS, 17: 1717–1730.PubMedCrossRefGoogle Scholar
  20. 20.
    Eltom M A, Jemal A, Mbulaiteye S M,et al. 2002. Trends in Kaposi’s sarcoma and non-Hodgkin’s lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst, 94: 1204–1210.PubMedGoogle Scholar
  21. 21.
    Ensoli B, Barillari G, Salahuddin S Z, et al.1990. Tat protein of HIV-1 stimulates growth of AIDS-Kaposi’s sarcoma-derived cells. Nature, 345: 84–86.PubMedCrossRefGoogle Scholar
  22. 22.
    Franceschi S, Maso L D, Rickenbach M,et al. 2008. Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Br J Cancer, 99: 800–804.PubMedCrossRefGoogle Scholar
  23. 23.
    Glesby M J, Hoover D R, Weng S,et al. 1996. Use of antiherpes drugs and the risk of Kaposi’s sarcoma: data from the Multicenter AIDS Cohort Study. J Infect Dis, 173: 1477–1480.PubMedGoogle Scholar
  24. 24.
    Grandadam M, Dupin N, Calvez V,et al. 1997. Exacerbations of clinical symptoms in human immunodeficiency virus type 1-infected patients with multicentric Castleman’s disease are associated with a high increase in Kaposi’s sarcoma herpesvirus DNA load in peripheral blood mononuclear cells. J Infect Dis, 175: 1198–1201.PubMedCrossRefGoogle Scholar
  25. 25.
    Grundhoff A, Ganem D. 2004. Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis. J Clin Invest, 113: 124–136.PubMedGoogle Scholar
  26. 26.
    Gustafson E A, Schinazi R F, Fingeroth J D. 2000. Human herpesvirus 8 open reading frame 21 is a thymidine and thymidylate kinase of narrow substrate specificity that efficiently phosphorylates zidovudine but not ganciclovir. J Virol, 74: 684–692PubMedCrossRefGoogle Scholar
  27. 27.
    He F, Wang X, He B,et al. 2007. Human herpesvirus 8: serovprevalence and correlates in tumor patients from Xinjiang, China. J Med Virol, 79: 161–166.PubMedCrossRefGoogle Scholar
  28. 28.
    Hocqueloux L, Agbalika F, Oksenhendler E,et al. 2001. Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy. AIDS, 15: 280–282PubMedCrossRefGoogle Scholar
  29. 29.
    Huang L M, Chao M F, Chen M Y,et al. 2001. Reciprocal regulatory interaction between human herpesvirus 8 and human immunodeficiency virus type 1. J Biol Chem, 276: 13427–13432.PubMedCrossRefGoogle Scholar
  30. 30.
    Ioannidis J P, Collier A C, Cooper D A,et al. 1998. Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. J Infect Dis, 178: 349–359.PubMedGoogle Scholar
  31. 31.
    Iwayama S, Ono N, Ohmura Y,et al. 1998. Antiherpesvirus activities of (1kS,2kR)-9-[[1k, 2k-bis (hydroxymethyl)-cycloprop-1k-yl]methyl] (A-5021) in cell culture. Antimicrob Agents Chemother, 42: 1666–1670.PubMedGoogle Scholar
  32. 32.
    Jung C, Bogner J R, Goebel F. 1998. Resolution of severe Kaposi’s sarcoma after initiation of antiretroviral triple therapy. Eur J Med Res, 3: 439–442.PubMedGoogle Scholar
  33. 33.
    Katano H, Sato Y, Kurata T,et al. 2000. Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi’s sarcoma, and multicentric Castleman’s disease. Virology, 269: 335–344.PubMedCrossRefGoogle Scholar
  34. 34.
    Katano H, Sato Y, Itoh H, Sata T. 2001. Expression of human herpesvirus 8 (HHV-8)-encoded immediate early protein, open reading frame 50, in HHV-8-associated diseases. J Hum Virol, 4: 96–102.PubMedGoogle Scholar
  35. 35.
    Katz M H, Hessol N A, Buchbinder S P,et al. 1994. Temporal trends of opportunistic infections and malignancies in homosexual men with AIDS. J Infect Dis, 170: 198–202.PubMedGoogle Scholar
  36. 36.
    Kedes D H, Ganem D. 1997. Sensitivity of Kaposi’s sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest, 99: 2082–2086.Google Scholar
  37. 37.
    Keller S A, Schattner E J, Cesarman E. 2000. Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood, 96: 2537–2542.PubMedGoogle Scholar
  38. 38.
    Krischer J, Rutschmann O, Hirschel B,et al. 1998. Regression of Kaposi’s sarcoma during therapy with HIV-1 protease inhibitors: a prospective pilot study. J Am Acad Dermatol, 38: 594–598PubMedCrossRefGoogle Scholar
  39. 39.
    Laney A S, Dollard S C, Jaffe H W,et al. 2004. Repeatedmeasures study of human herpesvirus 8 (HHV-8) DNA and antibodies in men seropositive for both HHV-8 and HIV. AIDS, 18: 1819–1826.PubMedCrossRefGoogle Scholar
  40. 40.
    Leao J C, Kumar N, McLean K A,et al. 2000. Effect of human immunodeficiency virus-1 protease inhibitors on the clearance of human herpesvirus 8 from blood of human immunodeficiency virus-1-infected patients. J Med Virol, 62: 416–420.PubMedCrossRefGoogle Scholar
  41. 41.
    Lebbe C, Blum L, Pellet C,et al. 1998. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi’s sarcoma. AIDS, 12: F45–49.PubMedCrossRefGoogle Scholar
  42. 42.
    Little R F, Merced-Galindez F, Staskus K,et al. 2003. A pilot study of cidofovir in patients with Kaposi sarcoma. J Infect Dis, 187: 149–153.PubMedCrossRefGoogle Scholar
  43. 43.
    Lock M J, Thorley N, Teo J,et al. 2002. Azidodeoxythymidine and didehydrodeoxythymidine as inhibitors and substrates of the human herpesvirus 8 thymidine kinase. J Antimicrob Chemother, 49: 359–366.PubMedCrossRefGoogle Scholar
  44. 44.
    Luppi M, Trovato R, Barozzi P,et al. 2005. Treatment of herpesvirus associated primary effusion lymphoma with intracavity cidofovir. Leukemia, 19: 473–476.PubMedCrossRefGoogle Scholar
  45. 45.
    Martin D F, Kuppermann B D, Wolitz R A,et al.1999. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. N Engl J Med, 340: 1063–1070.PubMedCrossRefGoogle Scholar
  46. 46.
    Martinelli C, Zazzi M, Ambu S,et al. 1998. Complete regression of AIDS-related Kaposi’s sarcoma-associated human herpesvirus-8 during therapy with indinavir. AIDS, 12: 1717–1719PubMedGoogle Scholar
  47. 47.
    Medveczky M M, Horvath E, Lund T,et al. 1997. In vitro antiviral drug sensitivity of the Kaposi’s sarcoma-associated herpesvirus. AIDS, 11: 1327–1332.PubMedCrossRefGoogle Scholar
  48. 48.
    Miller G, Heston L, Grogan E,et al. 1997. Selective switch between latency and lytic replication of KSV and EBV in dually infected body-cavity lymphoma cells, J Virol, 71: 314–324.PubMedGoogle Scholar
  49. 49.
    Mocroft A, Youle M, Gazzard B,et al. 1996. Anti-herpesvirus treatment and risk of Kaposi’s sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. AIDS, 10: 1101–1105.Google Scholar
  50. 50.
    Monini P, Colombini S, Sturzl M,et al. 1999. Reactivation and persistence of HHV-8 infection in B-cells and monocytes by Th1 cytokines increased in Kaposi’s sarcoma. Blood, 93: 4044–4058.PubMedGoogle Scholar
  51. 51.
    Murphy M, Armstrong D, Sepkowitz K A,et al. 1997. Regression of AIDS-related Kaposi’s sarcoma following treatment with an HIV-1 protease inhibitor. AIDS, 11: 261–262PubMedGoogle Scholar
  52. 52.
    Neyts J, Andrei G, Snoeck R,et al. 1994. The N-7-substituted acyclic nucleoside analog 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine is a potent and selective inhibitor of herpesvirus replication. Antimicrob Agents Chemother, 38: 2710–2716.PubMedGoogle Scholar
  53. 53.
    Neyts J, Jähne G, Andrei G,et al. 1995. In vivo antiherpesvirus activity of N-7-substituted acyclic nucleoside analog 2-amino-7-[(1,3-dihydroxy-2-propoxy) methyl] purine. Antimicrob Agents Chemother, 1995; 39: 56–60.PubMedGoogle Scholar
  54. 54.
    Neyts J, De Clercq E. 1997. Antiviral drug susceptibility of human herpesvirus 8. Antimicrob Agents Chemother, 41: 2754–2756.PubMedGoogle Scholar
  55. 55.
    Norbeck D W, Kern E, Hayashi S,et al. 1990. Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS. J Med Chem, 33: 1281–1285.PubMedCrossRefGoogle Scholar
  56. 56.
    Oksenhendler E, Carcelain G, Aoki Y,et al. 2000. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. Blood, 96: 2069–2073.PubMedGoogle Scholar
  57. 57.
    Pastore R D, Chadburn A, Kripas C,et al. 2000. Novel association of haemophagocytic syndrome with Kaposi’s sarcoma-associated herpesvirus-related primary effusion lymphoma. Br J Haematol, 111: 1112–1115.PubMedCrossRefGoogle Scholar
  58. 58.
    Pati S, Pelser C B, Dufraine J,et al. 2002. Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood, 99: 3771–3779.PubMedCrossRefGoogle Scholar
  59. 59.
    Pellet C, Chevret S, Blum L,et al. 2001. Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi’s sarcoma to highly active antiretroviral therapy. J Invest Dermatol, 117: 858–863.PubMedCrossRefGoogle Scholar
  60. 60.
    Portsmouth S, Stebbing J, Gill J,et al. 2003. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi’s sarcoma. AIDS, 17: F17–22.PubMedCrossRefGoogle Scholar
  61. 61.
    Rey D, Schmitt M P, Partisani M,et al. 2001. Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: a median follow-up of 64 weeks. J Acquir Immune Defic Syndr, 27: 459–462.PubMedGoogle Scholar
  62. 62.
    Schaeffer H J, Beauchamp L, de Miranda P,et al. 1978. 9-(2-Hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature, 272: 583–585.PubMedCrossRefGoogle Scholar
  63. 63.
    Schulz T F. 1999. Epidemiology of Kaposi’s sarcoma-associated herpesvirus/human herpesvirus 8. Adv Cancer Res, 76: 121–160.PubMedCrossRefGoogle Scholar
  64. 64.
    Sgadari C, Barillari G, Toschi E,et al. 2002. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med, 8: 225–232.PubMedCrossRefGoogle Scholar
  65. 65.
    Sgadari C, Monini P, Barillari G,et al. 2003. Use of HIV protease inhibitors to block Kaposi’s sarcoma and tumour growth. Lancet Oncol, 4: 537–547.PubMedCrossRefGoogle Scholar
  66. 66.
    Shimba N, Nomura A M, Marnett A B,et al. 2004. Herpesvirus protease inhibition by dimer disruption. J Virol, 78: 6657–6665.PubMedCrossRefGoogle Scholar
  67. 67.
    Smith M S, Bloomer C, Horvat R,et al. 1997. Detection of human herpesvirus 8 DNA in Kaposi’s sarcoma lesions and peripheral blood of human immunodeficiency virus-positive patients and correlation with serologic measurements. J Infect Dis, 176: 84–93.PubMedCrossRefGoogle Scholar
  68. 68.
    Tavio M, Nasti G, Spina M,et al. 1998. Highly active antiretroviral therapy in HIV-related Kaposi’s sarcoma. Ann Oncol, 9: 923–923.PubMedCrossRefGoogle Scholar
  69. 69.
    Valencia M E, Moreno V, Martinez P,et al. 2005. Favorable outcome of Castleman’s disease treated with oral valganciclovir. Med Clin (Barc), 125: 399.CrossRefGoogle Scholar
  70. 70.
    Wang J, Froeyen M, Hendrix C,et al. 2000. The cyclo-hexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclo-hexenyl-guanine. J Med Chem, 43: 736–745.PubMedCrossRefGoogle Scholar
  71. 71.
    Wilkinson J, Cope A, Gill J,et al. 2002. Identification of Kaposi’s sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconsti-tution of KSHV-specific responses in human immunodeficiency virus type 1-infectedpatients receivinghighly active antiretroviral therapy. J Virol, 76: 2634–2640.PubMedCrossRefGoogle Scholar
  72. 72.
    Ziegler J, Newton R, Bourboulia D,et al. 2003. Risk factors for Kaposi’s sarcoma: a case-control study of HIV-seronegative people in Uganda. Int J Cancer, 103: 233–240.PubMedCrossRefGoogle Scholar
  73. 73.
    Zietz C, Bogner J R, Goebel F D,et al. 1999. An unusual cluster of cases of Castleman’s disease during highly active antiretroviral therapy for AIDS. N Engl J Med, 340: 1923–1924.PubMedCrossRefGoogle Scholar

Copyright information

© Wuhan Institute of Virology, CAS and Springer-Verlag GmbH 2008

Authors and Affiliations

  1. 1.State Key Laboratory of Virology, Wuhan Institute of VirologyChinese Academy of SciencesWuhanChina

Personalised recommendations